Get the Stockscreener App
3.03
2.88%
-0.09
Protagenic Therapeutics Inc stock is traded at $3.03, with a volume of 71,706.
It is down -2.88% in the last 24 hours and down -15.79% over the past month.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
See More
Previous Close:
$3.12
Open:
$3.15
24h Volume:
71,706
Relative Volume:
0.23
Market Cap:
$1.79M
Revenue:
-
Net Income/Loss:
$-5.00M
P/E Ratio:
-2.6348
EPS:
-1.15
Net Cash Flow:
$-3.85M
1W Performance:
-2.57%
1M Performance:
-15.79%
6M Performance:
-64.98%
1Y Performance:
-85.47%
1-Day Range:
$3.00
$3.299
1-Week Range:
$2.80
$3.675
52-Week Range:
$2.35
$26.18
Protagenic Therapeutics Inc Stock (PTIX) Company Profile
Name
Protagenic Therapeutics Inc
Sector
Industry
Phone
(212) 994-8200
Address
149 FIFTH AVENUE, NEW YORK
Compare PTIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTIX
Protagenic Therapeutics Inc
|
3.03 | 1.67M | 0 | -5.00M | -3.85M | -1.15 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Protagenic Therapeutics Inc Stock (PTIX) Latest News
Protagenic Therapeutics, Inc.\new SEC 10-Q Report - TradingView
Protagenic Therapeutics Inc (PTIX) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Protagenic Therapeutics Announces Reverse Stock Split - TipRanks
Protagenic Therapeutics announces 1-for-14 reverse stock split - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Protagenic Takes Bold Step: 1-for-14 Reverse Split Aims to Preserve Nasdaq Listing - Stock Titan
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split - The Globe and Mail
Stock Surge: Protagenic Therapeutics Inc (PTIX) Closes at 0.23, Marking a -9.20 Increase/Decrease - DWinneX
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th - ACCESS Newswire
Stock Market Recap: Protagenic Therapeutics Inc (PTIX) Concludes at 0.28, a 0.69 Surge/Decline - DWinneX
PTIX stock touches 52-week low at $0.25 amid sharp annual decline - MSN
Protagenic Therapeutics stockholders approve reverse split authority - Investing.com Australia
Protagenic Therapeutics stockholders approve reverse split authority By Investing.com - Investing.com South Africa
What Did We Note About Insider Trading At Protagenic Therapeutics Inc (NASDAQ: PTIX)? - stocksregister.com
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Protagenic Therapeutics, Inc.\new SEC 10-K Report - TradingView
PTIX stock plunges to 52-week low, hitting $0.23 - Investing.com India
PTIX stock plunges to 52-week low, hitting $0.23 By Investing.com - Investing.com Australia
Protagenic Therapeutics (NASDAQ:PTIX) Stock Price Down 6.5% – Here’s Why - Defense World
BDSX Shrinks Loss With Revenue Growth, ALLR Plans $5Mln Share Buyback, What's The Buzz At PTIX? - RTTNews
PTIX stock plunges to 52-week low, hitting $0.25 By Investing.com - Investing.com Canada
Protagenic Therapeutics adjusts stock option prices By Investing.com - Investing.com South Africa
Protagenic Therapeutics adjusts stock option prices - Investing.com India
Protagenic Therapeutics Reprices Stock Options at Annual Meeting - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
PTIX’s Market Whiplash: -23.55% YTD Decline, -25.97% Plunge in 30 Days - The InvestChronicle
Stock Market Recap: Protagenic Therapeutics Inc (PTIX) Concludes at 0.37, a 11.82 Surge/Decline - The Dwinnex
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Protagenic Therapeutics Inc (PTIX) Shares Plummet Below 1-Year High - The News Heater
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Decrease in Short Interest - Defense World
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - ACCESS Newswire
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting - ACCESS Newswire
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - ACCESS Newswire
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split - ACCESS Newswire
Performance Tech Stock Hits 52-Week Low at $0.44 Amid Market Challenges - Investing.com
Protagenic Therapeutics, Inc. Enters into Amendment No. 1 to At Market Issuance Sales Agreement - Defense World
Protagenic Therapeutics Inc’s (PTIX) -12.44% Retreat Justifies A Second Look - Stocks Register
PTIX stock touches 52-week low at $0.45 amid market challenges - Investing.com Nigeria
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Protagenic Therapeutics (NASDAQ:PTIX) Faces Delisting Threat from NasdaqUnited States Securities and Exchange CommissionWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934D - Defense World
Protagenic Therapeutics faces Nasdaq delisting over equity deficit - Investing.com
PTIX stock touches 52-week low at $0.48 amid market challenges - Investing.com India
Galapagos NV (GLPG) Stock Surges Amid Strong Industry Performanc - GuruFocus.com
Protagenic Therapeutics Receives Delist Determination Letter from Nasdaq - Defense World
Protagenic Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Protagenic Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
ARMISTICE CAPITAL, LLC Acquires New Stake in Protagenic Therapeu - GuruFocus.com
Protagenic Therapeutics Inc Stock (PTIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):